Successful drug development
starts with biology
Can we make it? Could it be better?
Will it fill the need?
We're currently amidst an incredibly promising, challenging, era for gene delivery and cell therapies. Over the past decade of application and approval we’ve learned that effective drug development hinges on aligning patient needs with the bounds of biological and industrial possibility. At Co-Opt Consulting, our forte lies in bridging communication gaps throughout the drug development lifecycle, ensuring swift and effective assistance where it's needed most, without compromising quality.
In the journey towards delivering potentially life-changing therapies to patient populations and their caregivers, numerous hurdles must be overcome. Success in surmounting these challenges relies on a profound respect for the evidence generated during the stages of discovery and development. Addressing hurdles presented by IND-enabling studies, manufacturing capacity, regulatory compliance, patent filing and FTO, clinical trial design, and endpoints demands expert guidance that identifies issues preemptively, ultimately saving valuable time and resources.
Moreover, it's never too late to recalibrate strategy. Whether it's revitalizing a stagnant platform or preparing a program for its next phase, a comprehensive understanding of biology coupled with adept management of timelines, resources, and expectations is crucial.
What we offer
Co-Opt Consulting provides guidance to clarify your mission and de-risk activities to meet timelines and goals. Co-Opt specializes in setting early stage strategy and recommending action at junctures where time and resources limit the scope of exploration.
In conjunction with your own in-house expertise, Co-Opt Consulting can help set priorities, design a plan, and remain involved at all levels required to best guarantee your success.
Be it platform issues, informatics, candidate selection, process development, IND-enabling and other translational studies, analytical development, background on IP history and evaluation, or simply advice and diligence on third parties and others, Co-Opt Consulting can help.
About us
Co-Opt Consulting’s Chris Tipper is a drug developer specializing in gene and cell therapies with over 10 years of industry experience. He has worked at such pioneering now clinical-stage companies as bluebird bio, Dimension Tx, and Affinia Tx. He is a classically-trained molecular biologist with over 25 years of structural and evolutionary virology experience.
Why Co-opt?
Co-option is a term used by virologists to describe the hacking of a cellular pathway or mechanism by a virus for its own ends. Not only is co-option critical for production and delivery of advanced therapies, but we have learned much about ourselves by using these adaptations as tools for discovery.
Co-option more commonly means the acceptance of a new member to an established team—the seamless introduction of new skills and perspectives that Co-Opt Consulting aims to achieve with all clients.
Contact Us
Let us work together to determine if Co-opt is right for you. Please provide your preferred contact information and a brief description of your project and needs.
